Clinical features of patients with antisynthetase syndrome treated with anakinra.

Patient/CohortSex and Age, YrsClinical Manifestations and Antibody ProfileAcute-Phase Reactants and Ferritin LevelsTreatment Prior to AnakinraDaily Dosage of Anakinra, mgConcomitant Treatment
Our cohortPatient 1Male, 66Arthritis, fever, ILD, myopericarditis anti-PL12+IncreasedGC200GC
Patient 2Male, 55Fever, ILD, myocarditis, rash, Raynaud anti-PL12+IncreasedGC, AZA, MMF200GC
Patient 3Female, 54Fever, myocarditis, myositis, rash anti-Jo1+IncreasedGC, IVIG, MTX200GC, MTX
Literature reviewFurlan7Female, 60Arthritis, fever, ILD, myositis, rash anti-Jo1+IncreasedGC, CYA, CYC, MTX100GC, MTX
Zong8Male, 54Clinical manifestations NR anti-Jo1+NRAZA, CYC, IFX, IVIG, MTX100GC, AZA
Meudec9Female, 55Arthritis, ILD, myopericarditis, myositis anti-Jo1+NRMTX, RTXNRGC, MTX
Ahmad10Female, 65Arthritis, fever, ILD, rash anti-Jo1+IncreasedAZA, RTX, MMF100GC
  • AZA: azathioprine; CYC: cyclophosphamide; GC: glucocorticoid; IFX: infliximab; ILD: interstitial lung disease; IVIG: intravenous immunoglobulins; MMF: mycophenolate mofetil; MTX: methotrexate; NR: not reported; RTX: rituximab.